Abstract
Fixed dose combinations of Pantoprazole and Tetracycline (PT) have a wider range of susceptibility than any one of these two drugs individually. The present study was carried out to determine the Minimum Inhibitory Concentration (MIC) and Time kill curve of Pantoprazole, Tetracycline and a fixed dose combination of these two drugs in four groups (HP-B1, HP-B2, HP-B3, HP-B4) of Helicobacter pylori (H. pylori) bacteria. The MIC were found to be 0.03125 mg/l, 0.03125 mg/l, 0.03125 mg/l, and 0.0625 mg/l for PT, 32mg/l, 64mg/l, 32mg/l, 64mg/l, respectively, for Pantoprazole and 0.125 mg/l, 0.125mg/l, 0.125mg/l, and 0.25mg/l for tetracycline, respectively, in the different groups . In all H. pylori groups studied, the time-kill curve analysis demonstrated maximum bacterial killing at 4 hours with PT having the most pronounced effect. From the present findings it can be concluded that a fixed dose combination of pantoprazole and tetracycline has better efficacy and more bacterial inhibiting properties than Pantoprazole or Tetracycline alone.
Keywords: Minimum inhibitory concentration, time kill curve, fixed dose combination, pantoprazole, tetracycline
Current Drug Therapy
Title: Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection
Volume: 4 Issue: 2
Author(s): Dharmendra Rai, Vivek Kumar Dwivedi, Manu Chaudhary, Sanjay Mohan Shrivastava, Praveen Rishi and Pramod Kumar Pandey
Affiliation:
Keywords: Minimum inhibitory concentration, time kill curve, fixed dose combination, pantoprazole, tetracycline
Abstract: Fixed dose combinations of Pantoprazole and Tetracycline (PT) have a wider range of susceptibility than any one of these two drugs individually. The present study was carried out to determine the Minimum Inhibitory Concentration (MIC) and Time kill curve of Pantoprazole, Tetracycline and a fixed dose combination of these two drugs in four groups (HP-B1, HP-B2, HP-B3, HP-B4) of Helicobacter pylori (H. pylori) bacteria. The MIC were found to be 0.03125 mg/l, 0.03125 mg/l, 0.03125 mg/l, and 0.0625 mg/l for PT, 32mg/l, 64mg/l, 32mg/l, 64mg/l, respectively, for Pantoprazole and 0.125 mg/l, 0.125mg/l, 0.125mg/l, and 0.25mg/l for tetracycline, respectively, in the different groups . In all H. pylori groups studied, the time-kill curve analysis demonstrated maximum bacterial killing at 4 hours with PT having the most pronounced effect. From the present findings it can be concluded that a fixed dose combination of pantoprazole and tetracycline has better efficacy and more bacterial inhibiting properties than Pantoprazole or Tetracycline alone.
Export Options
About this article
Cite this article as:
Rai Dharmendra, Dwivedi Kumar Vivek, Chaudhary Manu, Shrivastava Mohan Sanjay, Rishi Praveen and Pandey Kumar Pramod, Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection, Current Drug Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488509788185196
DOI https://dx.doi.org/10.2174/157488509788185196 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry Endogenous BMP-4/ROS/COX-2 Mediated IPC and Resveratrol Alleviated Brain Damage
Current Pharmaceutical Design Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Cancer Stem Cells and Therapeutic Perspectives
Current Medicinal Chemistry Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies
Current Pharmaceutical Biotechnology Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design Immunohistochemical and Serological 90K / Mac-2BP Detection in Hepatocellular Carcinoma Patients: Different Behaviour of Two Monoclonal Antibodies
Medicinal Chemistry Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extracts
Anti-Cancer Agents in Medicinal Chemistry